Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20224059 | 0.91 | L3MBTL1 (0.38) | ELANENOTUML3MBTL1KMT2AALDH1A1 | |
| SCHEMBL20224081 | 0.87 | NOTUM (0.41) | ELANENOTUML3MBTL1KMT2AALDH1A1 | |
| SCHEMBL20977770 | 0.86 | KDM4E (0.36) | ELANEF2ALOX15KMT2AALDH1A1 | |
| SCHEMBL18054133 | 0.85 | ELANE (0.34) | ELANENOTUMALDH1A1 | |
| SCHEMBL20224053 | 0.84 | MEN1 (0.36) | NOTUMKMT2A | |
| SCHEMBL20224077 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL20224079 | 0.81 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL18052960 | 0.81 | KDM4E (0.35) | ELANENOTUMKMT2AALDH1A1 | |
| SCHEMBL20224065 | 0.81 | NOTUM (0.50) | NOTUMALDH1A1 | |
| SCHEMBL20224103 | 0.81 | NOTUM (0.33) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | ELANE 4633/4885NOTUM 4257/4885L3MBTL1 2715/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | ELANE 4589/4885NOTUM 4163/4885L3MBTL1 2644/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | ELANE 4589/4885NOTUM 4163/4885L3MBTL1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.